EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Continuous glucose monitoring metrics and pregnancy outcomes in insulin‐treated diabetes: A post‐hoc analysis of the GlucoMOMS trial

Doortje Rademaker iD, Anne W T van der Wel, Rik van Eekelen, Daphne N Voormolen, Harold W de Valk iD, Inge M Evers, Ben Willem Mol, Arie Franx, Sarah E Siegelaar, Bas B van Rijn, J Hans DeVries, Rebecca C Painter und 1 weitere

Diabetes, Obesity and Metabolism · 2023

DOI: 10.1111/dom.15276 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Doortje Rademaker und 12 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam UMC location University of Amsterdam, Department of Obstetrics and Gynecology, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Pre-Eclampsia, Premature Birth. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To investigate the association between continuous glucose monitoring (CGM) metrics and perinatal outcomes in insulin‐treated diabetes mellitus in pregnancy. Materials and Methods In a post‐hoc analysis of the GlucoMOMS randomized controlled trial, we investigated the association between the metrics of an offline, intermittent CGM, glycated haemoglobin (HbA1c) and perinatal outcomes per trimester in different types of diabetes (type 1, 2 or insulin‐treated gestational diabetes mellitus [GDM]). Data were analysed using multivariable binary logistic regression. Outcomes of interest were neonatal hypoglycaemia, pre‐eclampsia, preterm birth, large for gestational age (LGA) and Neonatal Intensive Care Unit (NICU) admission. The glucose target range was defined as 3.5–7.8 mmol/L (63–140 mg/dL).

Results

Of the 147 participants (N = 50 type 1 diabetes, N = 94 type 2 diabetes/insulin‐treated GDM) randomized to the CGM group of the GlucoMOMS trial, 115 participants had CGM metrics available and were included in the current study. We found that, in pregnancies with type 1 diabetes, a higher second trimester mean glucose was associated with LGA (odds ratio 2.6 [95% confidence interval 1.1–6.2]). In type 2 and insulin‐treated gestational diabetes, an increased area under the curve above limit was associated with LGA (odds ratio 10.0 [95% confidence interval 1.4–72.8]). None of the CGM metrics were associated with neonatal hypoglycaemia, pre‐eclampsia, shoulder dystocia, preterm birth and NICU admission rates for pregnancies complicated by any type of diabetes.

Conclusion

In this study, in type 2 diabetes or insulin‐treated GDM, the glucose increased area under the curve above limit was associated with increased LGA. In type 1 diabetes, the mean glucose was the major determinant of LGA. Our study found no evidence that other CGM metrics determined adverse pregnancy outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2Pre-EclampsiaPremature BirthDiabetes, GestationalHypoglycemiaPregnancyFemaleInfant, NewbornHumansPregnancy OutcomeInsulinBlood GlucoseBlood Glucose Self-MonitoringInsulin, Regular, HumanGlucose

Stichwörter der Autor:innen

continuous glucose monitoringdiabetes in pregnancygestational diabeteslarge-for-gestational age

Substanzen

InsulinBlood GlucoseInsulin, Regular, HumanGlucose

Autor:innen und Institutionen

  • Amsterdam UMC location University of Amsterdam, Department of Obstetrics and Gynecology, Amsterdam, The Netherlands.
  • Amsterdam Reproduction & Development Research Institute, Amsterdam, The Netherlands.
  • Department of Obstetrics and Gynecology, WKZ, Utrecht, The Netherlands.
  • Department of Endocrinology, University Medical Centre Utrecht, Utrecht, The Netherlands.
  • Department of Obstetrics and Gynecology, Amersfoort, The Netherlands.
  • Department of Obstetrics and Gynecology, Monash University, Clayton, Victoria, Australia.

ORCID-Profile: Doortje Rademaker, Harold W de Valk

Förderung

  • ZonMw

Zitieren

APA

Rademaker, D., van der Wel, A. W. T., van Eekelen, R., Voormolen, D. N., de Valk, H. W., Evers, I. M., Mol, B. W., Franx, A., Siegelaar, S. E., van Rijn, B. B., DeVries, J. H., Painter, R. C., & GlucoMOMS studygroup (2023). Continuous glucose monitoring metrics and pregnancy outcomes in insulin‐treated diabetes: A post‐hoc analysis of the GlucoMOMS trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15276

Vancouver

Rademaker D, van der Wel AWT, van Eekelen R, Voormolen DN, de Valk HW, Evers IM, et al. Continuous glucose monitoring metrics and pregnancy outcomes in insulin‐treated diabetes: A post‐hoc analysis of the GlucoMOMS trial. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15276

BibTeX
@article{Rademaker2023,
  author = {Rademaker, Doortje and van der Wel, Anne W T and van Eekelen, Rik and Voormolen, Daphne N and de Valk, Harold W and Evers, Inge M and Mol, Ben Willem and Franx, Arie and Siegelaar, Sarah E and van Rijn, Bas B and DeVries, J Hans and Painter, Rebecca C and GlucoMOMS studygroup, GlucoMOMS studygroup},
  title = {Continuous glucose monitoring metrics and pregnancy outcomes in insulin‐treated diabetes: A post‐hoc analysis of the GlucoMOMS trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  doi = {10.1111/dom.15276}
}
Kostenlos starten →